Product · #8 of 27 · multi-symptom (single active)
Estroven Complete Multi-Symptom Menopause Relief
Caplet from Estroven, made by i-Health (dsm-firmenich). Daily serving: 1 caplet.
Last updated · Price and ratings checked Nov 19, 2026
In short: Estroven Complete Multi-Symptom Menopause Relief scores 55.0/100 in our ranking (#8 of 27). It costs $0.71 a day at the regular price. Evidence: ERr 731 at the trial dose (4 mg); no Estroven-specific trial; best ingredient grade C (ERr 731 rhapontic rhubarb). No NSF registry listing was confirmed.
Pros
- Widely reviewed: ★ 4.4 from 19,727 Amazon ratings.
- Evidence: ERr 731 at the trial dose (4 mg); no Estroven-specific trial.
Cons
- No NSF registry listing confirmed.
- Legal or regulatory history: see flags below.
Flags
Class actionWatchdog complaint
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Rhapontic rhubarb root extract ERr 731 (Rheum rhaponticum) – provides 2.2 mg rhaponticin + 1 mg desoxyrhaponticin | 4 mg | ERr 731 rhapontic rhubarb C |
Amazon #1 best seller in its menopause category and described as the #1 pharmacist-recommended brand (Pharmacy Times OTC survey), per the research notes. ERr 731 has several placebo-controlled trials; Estroven itself has no product-specific trial.
Evidence
Our evidence score: 27/40, because: ERr 731 at the trial dose (4 mg); no Estroven-specific trial.
Product-level research: No Estroven-specific RCT found on PubMed; site cites ERr 731 ingredient trials. Its '90% reduction' claim derives from ingredient studies. Other Estroven SKUs add Sensoril ashwagandha. Evidence grade for the branded product: C C (borrowed ingredient evidence).
Ingredient evidence
- ERr 731 rhapontic rhubarb C (4 mg here)
ERr 731 is a rhapontic rhubarb root extract (the active in Estroven Complete) studied in perimenopausal women for occasional hot flashes and related symptoms*. The placebo-controlled trials come from one research group. The Menopause Society 2023: Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study.
Studies
Studies on its ingredients (4)
-
Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.
109 perimenopausal women took the rhubarb-root extract ERr 731 (sold as Estrovera/Estroven Complete) or placebo for 12 weeks. Symptoms including hot flashes improved strongly. However, most women on placebo dropped out, which makes the comparison less reliable.
- Who
- 109 perimenopausal women
- Dose
- ERr 731 one tablet/day (4 mg)
- Duration
- 12 weeks
- Result
- MRS total and each symptom improved vs placebo (P<.0001); fewer and milder hot flushes from week 4; no endometrial changes. NAMS notes only 7/55 placebo completers.
- Funding
- Authors from Health Research Services Ltd; manufacturer (Dr. Loges) funding not stated in abstract. Industry-linked
-
Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
A second 12-week trial by the same research group (112 women) again found large improvements with ERr 731 versus placebo. Independent replication is still lacking.
- Who
- 112 perimenopausal women
- Dose
- ERr 731 one tablet/day
- Duration
- 12 weeks
- Result
- MRS total 27.0→12.4 vs 27.0→24.0 placebo (P<.0001); hot flushes reduced.
- Funding
- Same research group as the original trial; funding not stated in abstract. Industry-linked
-
Efficacy evaluation of standardized Rheum rhaponticum root extract (ERr 731 (®)) on symptoms of menopause: A systematic review and meta-analysis study.
A pooled analysis of 4 ERr 731 studies found large symptom reductions, but the analysis was written by staff of a company that sells the extract.
- Who
- 4 studies, 390 women
- Dose
- ERr 731
- Duration
- 12 weeks
- Result
- Pooled MRS reduction -15.1 points vs control (P<.001).
- Funding
- Lead authors from Sundyota Numandis (Indian distributor) – industry-affiliated. Industry-linked
-
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
In German medical records, women prescribed ERr 731 were not more likely to be diagnosed with breast cancer than women who were not. This is observational, partly industry-linked data.
- Who
- 5,686 users vs 17,058 non-users (German records)
- Dose
- ERr 731 prescriptions
- Duration
- observational
- Result
- No increase in breast-cancer diagnosis (OR 1.01, 95% CI 0.81–1.26).
- Funding
- Two authors employed by Health Research Services GmbH. Industry-linked
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $19.99 (28 units, 28 days at label dose) |
|---|---|
| Cost per day | $0.71 |
| Subscription | $17.99 (28 ct) brand subscribe; Amazon S&S $13.28 during BF |
| Price notes | 28 ct $19.99 (60 ct $29.99 = $0.50/day). Amazon B07N813336 list $19.99, Black Friday $13.98. |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.4 from 19,727 ratings on Amazon (checked Nov 19, 2026)
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “hormone-free” Brand claim
- “drug-free” Brand claim
- “soy-free (Complete line only)” Brand claim
- “gluten-free” Brand claim
- “vegan-suitable (caplet)” Brand claim
Registry check: NSF/ANSI 173 (searched 'Estroven', 'i-Health'): not found
Who's behind it
| Brand | Estroven |
|---|---|
| Owner / company | i-Health, Inc. (Cromwell, CT), part of the dsm-firmenich group (estroven.com footer '© 2026 dsm-firmenich group'). |
| Founders | Not stated on the pages we read. |
| Where it's made | Older label: 'Made in the USA with US and imported materials' (Weight Management SFP); not stated for others. |
| Medical advisors named |
|
| Source | estroven.com |
Flags & safety
Legal, regulatory and quality flags
- Class action Arnold v. I-Health, Inc. (C.D. Cal. 2:26-cv-01282, filed 2026) alleges Estroven Mood Boost and Stress Relief claims are false/misleading (not the Complete SKU). classaction.org
- TINA.org warning letter to i-Health re menopause marketing (Oct 2024). truthinadvertising.org
Ingredient safety notes
- ERr 731 rhapontic rhubarb: Post-marketing (Germany, ~140M daily doses): mainly hypersensitivity and GI complaints. Observational German data: no increase in breast-cancer diagnosis (OR 1.01, industry-linked). Endometrium unchanged in trials. Contains ER-β–active compounds.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.